EA021994B1 - Антагонисты мускариновых рецепторов ацетилхолина - Google Patents

Антагонисты мускариновых рецепторов ацетилхолина Download PDF

Info

Publication number
EA021994B1
EA021994B1 EA201100019A EA201100019A EA021994B1 EA 021994 B1 EA021994 B1 EA 021994B1 EA 201100019 A EA201100019 A EA 201100019A EA 201100019 A EA201100019 A EA 201100019A EA 021994 B1 EA021994 B1 EA 021994B1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
hydroxy
oxy
diphenyl
octane bromide
Prior art date
Application number
EA201100019A
Other languages
English (en)
Russian (ru)
Other versions
EA201100019A1 (ru
Inventor
Драман И. Лэн
Майкл Р. Палович
Брент У. Макклеланд
Кристофер Э. Нейпп
Соня М. Томас
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA021994(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA201100019A1 publication Critical patent/EA201100019A1/ru
Publication of EA021994B1 publication Critical patent/EA021994B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
EA201100019A 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина EA021994B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27

Publications (2)

Publication Number Publication Date
EA201100019A1 EA201100019A1 (ru) 2011-12-30
EA021994B1 true EA021994B1 (ru) 2015-10-30

Family

ID=35242158

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100019A EA021994B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина
EA200601991A EA015033B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200601991A EA015033B1 (ru) 2004-04-27 2005-04-27 Антагонисты мускариновых рецепторов ацетилхолина

Country Status (38)

Country Link
US (9) US7498440B2 (enEXAMPLES)
EP (3) EP1740177B1 (enEXAMPLES)
JP (2) JP5014121B2 (enEXAMPLES)
KR (2) KR101037026B1 (enEXAMPLES)
CN (2) CN1976701A (enEXAMPLES)
AP (1) AP2213A (enEXAMPLES)
AR (1) AR050902A1 (enEXAMPLES)
AU (1) AU2005237576B2 (enEXAMPLES)
BE (1) BE2014C063I2 (enEXAMPLES)
BR (1) BRPI0510170B8 (enEXAMPLES)
CA (2) CA2755954C (enEXAMPLES)
CY (3) CY1113196T1 (enEXAMPLES)
DK (2) DK2570128T3 (enEXAMPLES)
EA (2) EA021994B1 (enEXAMPLES)
EC (1) ECSP066940A (enEXAMPLES)
ES (2) ES2600405T3 (enEXAMPLES)
FR (1) FR14C0075I2 (enEXAMPLES)
HR (2) HRP20120832T1 (enEXAMPLES)
HU (2) HUE031304T2 (enEXAMPLES)
IL (1) IL178152A (enEXAMPLES)
LT (1) LT2570128T (enEXAMPLES)
LU (1) LU92565I2 (enEXAMPLES)
MA (1) MA28631B1 (enEXAMPLES)
MX (1) MXPA06012405A (enEXAMPLES)
MY (1) MY144753A (enEXAMPLES)
NL (1) NL300694I2 (enEXAMPLES)
NO (3) NO338959B1 (enEXAMPLES)
NZ (1) NZ549997A (enEXAMPLES)
PE (1) PE20060259A1 (enEXAMPLES)
PL (2) PL2570128T3 (enEXAMPLES)
PT (2) PT1740177E (enEXAMPLES)
SG (1) SG186597A1 (enEXAMPLES)
SI (2) SI2570128T1 (enEXAMPLES)
TW (1) TWI363759B (enEXAMPLES)
UA (1) UA95768C2 (enEXAMPLES)
UY (1) UY28871A1 (enEXAMPLES)
WO (1) WO2005104745A2 (enEXAMPLES)
ZA (1) ZA200608565B (enEXAMPLES)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046114A1 (es) * 2003-10-17 2005-11-23 Glaxo Group Ltd Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1732547B1 (en) * 2004-04-05 2008-08-20 Samaritan Pharmaceuticals, Inc. Anti-hiv quinuclidine compounds
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US7598267B2 (en) * 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
WO2007022351A2 (en) * 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
PL3578169T3 (pl) 2009-02-26 2024-09-02 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
EP2406255B1 (en) 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
TWI562992B (en) 2009-04-30 2016-12-21 Glaxo Group Ltd Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
CA2788364C (en) * 2010-01-28 2017-10-31 Theron Pharmaceuticals, Inc. 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
SG186427A1 (en) * 2010-06-22 2013-01-30 Chiesi Farma Spa Dry powder formulation comprising an antimuscarinic drug
PT2614058E (pt) 2010-09-08 2015-10-27 Glaxosmithkline Ip Dev Ltd Polimorfos e sais de n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4- morfolinil]metil}-1,3-oxazol-2-il)-1h-indazol-6-il]-2- (metiloxi)-3-piridinil]metanossulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2012168160A1 (en) 2011-06-08 2012-12-13 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
PH12013502497A1 (en) 2011-06-08 2019-07-17 Glaxo Group Ltd Combination comprising umeclidinium and a corticosteroid
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
US9273001B2 (en) * 2012-08-15 2016-03-01 Glaxo Group Limited Chemical process
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
RU2641285C2 (ru) * 2013-07-13 2018-01-17 Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд Соединения хинина, способ их получения и их медицинское применение
US20150037269A1 (en) * 2013-07-30 2015-02-05 Glaxosmithkline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
EP3057587A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
KR20160062178A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
CR20160529A (es) 2014-05-12 2017-01-02 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas para tratar enfermedades infecciosas
EP4252742A3 (en) 2014-05-28 2023-12-27 GlaxoSmithKline Intellectual Property Development Ltd Fluticasone furoate in the treatment of copd
CA2965590A1 (en) 2014-11-03 2016-05-12 Olon S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
CN108473437B (zh) * 2016-01-08 2022-03-25 西伦制药公司 7-氮杂双环[2.2.1]庚烷衍生物的干粉吸入器组合物
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
WO2018029126A1 (en) 2016-08-08 2018-02-15 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) * 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (enEXAMPLES) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
PT77471B (en) 1982-10-08 1986-08-19 Glaxo Group Ltd Devices for administering medicaments to patients
GB2178965B (en) 1985-07-30 1988-08-03 Glaxo Group Ltd Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
JP2001505576A (ja) * 1996-12-02 2001-04-24 ジョージタウン ユニバーシティ トロパン誘導体類及びそれらの合成方法
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
IL160896A0 (en) * 2001-10-17 2004-08-31 Ucb Sa Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
BR0214016A (pt) * 2001-11-09 2004-10-13 Upjohn Co Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr
IL162596A0 (en) * 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
PE20040892A1 (es) 2002-08-06 2004-11-19 Glaxo Group Ltd Antagonistas del receptor muscarinico m3 de acetilcolina
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AR045913A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
TW200519109A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
ATE494285T1 (de) 2003-10-14 2011-01-15 Glaxo Group Ltd Muscarinische acetylcholin-rezeptor-antagonisten
AR046114A1 (es) 2003-10-17 2005-11-23 Glaxo Group Ltd Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
JP4851937B2 (ja) * 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20090253908A1 (en) 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
EP1751089A4 (en) 2004-03-11 2010-03-10 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
JP2007529511A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005094834A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094835A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005099706A2 (en) 2004-04-07 2005-10-27 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
TWI363759B (en) * 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US7598267B2 (en) 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2005118594A1 (en) 2004-05-28 2005-12-15 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1765339A4 (en) 2004-06-30 2009-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
US20070293531A1 (en) 2004-08-05 2007-12-20 Jakob Busch-Petersen Muscarinic Acetycholine Receptor Antagonists
JP2008509158A (ja) 2004-08-06 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20090142279A1 (en) 2004-11-15 2009-06-04 Budzik Brian W Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US20080234315A1 (en) 2005-08-02 2008-09-25 Jakob Busch-Petersen M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007022351A2 (en) 2005-08-18 2007-02-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEDA, K et al. M3 receptor angagonism by the novel antimuscarmic agent solifenacin in the urinary bladder and salivary gland, Naimyn-Schmiedeberg's Arch Pharmacol, 2002, vol. 366, pages 97-103, abstract *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358908B2 (en) 2020-04-26 2025-07-15 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
AU2005237576A1 (en) 2005-11-10
WO2005104745A2 (en) 2005-11-10
IL178152A (en) 2011-05-31
MY144753A (en) 2011-10-31
NZ549997A (en) 2010-10-29
ZA200608565B (en) 2019-12-18
EA200601991A1 (ru) 2007-02-27
AU2005237576B2 (en) 2012-01-12
US20130030015A1 (en) 2013-01-31
CY2014043I2 (el) 2015-12-09
PL1740177T3 (pl) 2012-12-31
KR101037026B1 (ko) 2011-05-25
SI1740177T1 (sl) 2012-12-31
HUS1400053I1 (hu) 2017-07-28
CN1976701A (zh) 2007-06-06
EP2570128B1 (en) 2016-08-10
UY28871A1 (es) 2005-11-30
US20150238470A1 (en) 2015-08-27
EA201100019A1 (ru) 2011-12-30
US9144571B2 (en) 2015-09-29
BRPI0510170B1 (pt) 2018-12-18
BE2014C063I2 (enEXAMPLES) 2024-08-08
US20140371264A1 (en) 2014-12-18
BRPI0510170A (pt) 2007-10-02
LU92565I9 (enEXAMPLES) 2019-01-17
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
MA28631B1 (fr) 2007-06-01
US20160002220A1 (en) 2016-01-07
CY1118082T1 (el) 2017-06-28
KR101152032B1 (ko) 2012-06-11
CA2564742A1 (en) 2005-11-10
LU92565I2 (fr) 2014-12-02
NO2017018I1 (no) 2017-05-04
US8853404B2 (en) 2014-10-07
CA2755954A1 (en) 2005-11-10
US20090124653A1 (en) 2009-05-14
ECSP066940A (es) 2006-12-20
US7488827B2 (en) 2009-02-10
JP2007534769A (ja) 2007-11-29
KR20110010841A (ko) 2011-02-07
NL300694I1 (enEXAMPLES) 2015-12-29
PE20060259A1 (es) 2006-03-25
JP5014121B2 (ja) 2012-08-29
NO2017018I2 (no) 2018-05-14
AP2006003746A0 (en) 2006-10-31
CY1113196T1 (el) 2015-12-09
CN102040602A (zh) 2011-05-04
TW200605887A (en) 2006-02-16
JP2012162559A (ja) 2012-08-30
EP1740177A4 (en) 2010-05-05
UA95768C2 (ru) 2011-09-12
HUE031304T2 (hu) 2017-07-28
DK2570128T3 (en) 2016-11-07
NL300694I2 (enEXAMPLES) 2015-12-29
EP1740177B1 (en) 2012-08-08
EP1740177A2 (en) 2007-01-10
EP2570128A1 (en) 2013-03-20
NO2017017I1 (no) 2017-05-04
WO2005104745A3 (en) 2006-08-03
IL178152A0 (en) 2006-12-31
PL2570128T3 (pl) 2017-09-29
EA015033B1 (ru) 2011-04-29
PT2570128T (pt) 2016-10-07
LT2570128T (lt) 2016-10-10
NO338959B1 (no) 2016-11-07
DK1740177T3 (da) 2012-10-29
MXPA06012405A (es) 2007-01-17
HRP20120832T1 (hr) 2012-11-30
SI2570128T1 (sl) 2016-11-30
US8183257B2 (en) 2012-05-22
ES2600405T3 (es) 2017-02-08
ES2392848T3 (es) 2012-12-14
US20120157491A1 (en) 2012-06-21
PT1740177E (pt) 2012-11-02
US9045469B2 (en) 2015-06-02
EP3111936A1 (en) 2017-01-04
CY2014043I1 (el) 2015-12-09
AP2213A (en) 2011-03-01
CA2564742C (en) 2012-01-10
US8309572B2 (en) 2012-11-13
ES2392848T4 (es) 2014-10-01
US8575347B2 (en) 2013-11-05
JP5398871B2 (ja) 2014-01-29
FR14C0075I2 (fr) 2015-05-22
FR14C0075I1 (fr) 2014-11-21
CA2755954C (en) 2014-02-18
AR050902A1 (es) 2006-12-06
KR20070015412A (ko) 2007-02-02
SG186597A1 (en) 2013-01-30
NO20065417L (no) 2006-12-29
US20070185155A1 (en) 2007-08-09
US7498440B2 (en) 2009-03-03
HK1102423A1 (en) 2007-11-23
HRP20161385T1 (hr) 2016-12-02
BRPI0510170B8 (pt) 2021-05-25
TWI363759B (en) 2012-05-11

Similar Documents

Publication Publication Date Title
EA021994B1 (ru) Антагонисты мускариновых рецепторов ацетилхолина
CN1906183B (zh) N-酰基磺酰胺细胞程序死亡促进剂
KR100362620B1 (ko) 알레르기성질환치료에유용한치환된피페리딘,이를포함하는약제학적조성물및이의제조방법
RU2365588C2 (ru) Хиназолиновые соединения
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
JP4505227B2 (ja) １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
EP0844877B1 (en) Use of oxido-squalene cyclase inhibitors to lower blood cholesterol
DE60107221T2 (de) Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
JP2009540013A5 (enEXAMPLES)
RU2006127572A (ru) Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
JP2024532374A (ja) Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
JP2003535887A5 (enEXAMPLES)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2004110717A (ru) Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов
WO2001025228A1 (fr) Derives d'amines
JPWO2005097738A1 (ja) 新規スルホンアミド誘導体
JPWO2020038415A5 (enEXAMPLES)
BRPI0213393B1 (pt) derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
JP2004525892A5 (enEXAMPLES)
NL1028193C2 (nl) Farmaceutisch werkzame verbindingen.
JP2002505286A5 (enEXAMPLES)
EP0775138B1 (en) TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO 2,3-b]PYRIDINE
PT1907374E (pt) Derivados de benzilpiperazina úteis para o tratamento de doenças gastrointestinais
JP2004507527A5 (enEXAMPLES)
CN102131777B (zh) Ccr2的哌啶基丙烯酰胺拮抗剂

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM